Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ODTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| OD-07656 | Ulcerative Colitis (UC) | Phase 2 · NCT06850727 | Recruiting |
| [14C]OD-001 | Health Volunteers | Phase 1 · NCT07900607 | Recruiting |
| PRV-002 | Traumatic Brain Injury (TBI) | Phase 1 · NCT05033444 | Completed |
Also used in these trials (approved or third-party drugs, not ODTX's own candidates): Vedolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ODTX holds $387M in cash and short-term investments (as of Sep 30, 2026) and burns about $38M/quarter from operations, an estimated runway of 30.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund our operating expenses and capital expenditures into the second half of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ODTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 6,239,237 | 12.98% | 2026-09-30 |
| SR ONE CAPITAL MANAGEMENT, LLC 10% owner |
Insider | 3,794,883 | 7.89% | 2026-05-11 |
| TPG GP A, LLC Former 10% Owner |
Insider | 3,690,146 | 7.68% | 2026-05-11 |
| Jeito II S.L.P. | 5%+ holder (13D) | 3,690,145 | 7.68% | 2026-05-08 |
| Lightspeed Venture Partners XV-B (Ignite | 5%+ holder (13G) | 3,608,443 | 7.51% | 2026-05-11 |
| Lightspeed Management Company, L.L.C. | Institution (13F) | 3,608,443 | 7.51% | 2026-09-30 |
| Nan (LN) Li Director |
Insider | 3,333,516 | 6.94% | 2026-05-11 |
| Dimension Capital II, L.P. Director Includes shares also reported by Nan (LN) Li, counted once |
Insider | 3,333,516 | 6.94% | 2026-05-08 |
| Dimension Management, L.P. | Institution (13G, 5%+) | 3,333,516 | 6.94% | 2026-05-08 |
| Orbimed Advisors LLC. | Institution (13F) | 3,001,198 | 6.24% | 2026-09-30 |
| Sanofi | Institution (13F) | 1,990,200 | 4.14% | 2026-09-30 |
| MPM Bioimpact LLC | Institution (13F) | 1,289,091 | 2.68% | 2026-09-30 |
Share count 48,067,877 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ODTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →